Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CNSY
Cerenome, Inc. (CNSY) EV/Sales
As of 16 October 2026, Cerenome, Inc. (CNSY) trades at a EV/Sales of 3.3×. Over the past ten years it has ranged from −10.7× (March 2023) to 62,881,478× (March 2015); the current reading is higher than 49% of that period. That is below the Biotechnology industry median of 9.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | 256.62% |
| FY2024 | 1.9× | 86.77% |
| FY2023 | 1.0× | — |
| FY2022 | −8.7× | — |
| FY2020 | 1.2× | — |
| FY2019 | −0.4× | — |
| FY2018 | 6.5× | (20.71%) |
| FY2017 | 8.2× | (100.00%) |
| FY2016 | 1,114,112× | 7.47% |
| FY2015 | 1,036,719× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.7× | 149.60% |
| Mar 2026 | 3.1× | (54.82%) |
| Dec 2025 | 6.8× | (43.70%) |
| Sep 2025 | 12.1× | 274.83% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | −66.3× |
| LPCN Lipocine Inc. compare | −5.2× |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| RVLP RVL Pharmaceuticals PLC compare | 1.0× |
| CLVSQ Clovis Oncology, Inc. compare | 3.1× |
| CNSY Cerenome, Inc. | 3.3× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| TVRD Tvardi Therapeutics, Inc. compare | 4.8× |
| BCDA BioCardia, Inc. compare | 30.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)